Here we report that Niaspan, an extended release formulation of nicotinic acid/niacin, which is thought to enhance Tace activity (Chen et al, 2007, 2009), ameliorates the neuropathy in the Mtmr2 (myotubularin‐related protein 2)−/− mouse, a model of CMT4B1 with myelin outfoldings (Bolino et al, 2000, 2004; Bolis et al, 2005), and in the Pmp22 (peripheral myelin protein 22)+/− mouse, which reproduces HNPP (hereditary neuropathy with liability to pressure palsies) with tomacula (Adlkofer et al, 1995). The gene discussed is PMP22; the disease is neuropathy.